Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Fig. 2

Survival analysis in each cohort with different characteristics and treatment strategies. Median intracranial progression-free survival (iPFS) in A the BM cohort, and B the LM cohort with different physical status. Median iPFS in C the BM cohort, and D the LM cohort who had treated with other third-generation TKI prior to furmonertinib or not. Median iPFS in E the BM cohort, and F the LM cohort treated with furmonertinib 160 mg monotherapy or in combination with anti-angiogenic agent

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us